Home Earnings Analysis Healthcare  Summary Boston Scientific Corporation is a leading medtech innovator facing recent share price underperformance due to market share erosion in electrophysiology and sector-wide sentiment shifts. Despite competitive pressures, BSX maintains strong leadership in PFA, with Watchman and neuromodulation as promising growth drivers and a robust pipeline supported by strategic M&A. Management has improved operating and net margins, reduced short-term debt, and achieved ROIC above WACC, signaling efficient capital allocation and resilience despite slowing revenue growth. At historically low valuations and with sector sentiment near troughs, I rate BSX a Hold for now, favoring patience until EP market share stabilizes and sector rotation materializes. Monty Rakusen/DigitalVision via Getty Images Boston Scientific Corporation ( BSX ) was founded in 1979 and is headquartered in Massachusetts.…